Evidence map›Paper›PMID 40517347›Full record

ArticleMolecular diversity2026

Design and synthesis of 2-amino-4-(trifluoromethyl)pyrimidine derivatives as potential Werner-dependent antiproliferative agents.

Chang You, Shijiao Wei, Jia Yu, Guangcan Xu, Huimin Li, Xinyu Liu, Menghan Wang, Xueling Meng, Youyin Xu, Gang Yu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chang You *College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China.
Shijiao Wei *State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550014, China.
Jia YuState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550014, China.
Guangcan XuState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550014, China.
Huimin LiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550014, China.
Xinyu LiuState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550014, China.
Menghan WangCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China.
Xueling MengState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550014, China.
Youyin XuCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China.
Gang YuState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550014, China.
Heng LuoState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550014, China. luo_heng@gmc.edu.cn.
Bixue XuState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550014, China. bixue_xu@126.com.

Funding

National Natural Science Foundations of China 82260675Natural Science Foundation of Guizhou Province QKHJC-ZK[2022]YB298Natural Science Foundation of Guizhou Province QKHJC-ZK[2022]ZD031the Guizhou Province "Hundred" Level Innovative Talent Training Project QKHPTRC-GCC [2022]034-1
6 · The paper itself

Abstract

To uncover novel inhibitors of Werner (WRN) helicase, this study adopted the scaffold-hopping strategy to design and synthesize 24 novel 2-amino-4-(trifluoromethyl)pyrimidine derivatives. The MTT assay was employed to evaluate the anticancer activity of target compounds against microsatellite instability-high (MSI-H) cell lines (HCT116 and LNCaP) and microsatellite stability (MSS) cell lines (SW620 and PC3). Some compounds demonstrated significant inhibitory activity against all four cancer cell lines. Specifically, compounds 11c, 11f, 11 g, 11 h, and 11 l exhibited greater inhibitory effect toward MSI-H cells (HCT116 and LNCaP) compared to MSS cells (SW620 and PC3). The most active compound 11 g exhibited excellent cellular selectivity, with IC

Indexed as

Antineoplastic AgentsDrug DesignPyrimidinesWerner Syndrome HelicaseApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsPyrimidinesWerner Syndrome HelicaseWRN protein, human2-aminopyrimidine-4-(trifluoromethyl)AntiproliferativeWerner helicase

Identifiers

PMID40517347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.